Additional benefits of broad NGS testing include the ability to better characterize the biology of the tumor to identify potential areas of study for clinical trials or potential future therapies, as well as provide potentially prognostic information.37 Noteworthy examples of this are the recent targetability of KRAS G12C mutations, and the intriguing use of antibody-drug conjugates for HER2-mutated NSCLC. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.